ATLANTA, GA – – (January 31, 2018) – – Holzer & Holzer, LLC is investigating whether MabVax Therapeutics Holdings, Inc. (“MabVax” or the “Company”) (NASDAQ: MBVX) complied with the federal securities laws. On January 30, 2018, MabVax announced that it received notice that the Securities and Exchange Commission (“SEC”) is investigating and examining certain of the Company’s filed registration statements and subsequent amendments. The price of MabVax stock fell significantly following the announcement. If you purchased MabVax common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer Esq. at firstname.lastname@example.org or Alexandria P. Rankin, Esq. at email@example.com, or call the firm by toll-free telephone at (888) 508-6832.